The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study
IntroductionIn mainland China, trastuzumab deruxtecan was first authorized in February 2023 as a monotherapy for the treatment of patients with HER-2-positive adult breast cancer who were either unresectable or had metastasized after receiving one or more anti-HER-2 treatments. In July 2023, trastuz...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1582498/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|